Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABC-02: Gemcitabine +/- Cisplatin in Biliary Tract Cancer
NCT00262769Phase 3Completed
- Sponsor
- University College London
- Start
- May 2005
- Primary completion
- Aug 2008
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Cisplatin micelle injection (HA132) in biliary tract cancer (BTC) (2 arms), sponsored by University College London. Primary endpoint: Overall Survival at 5 years. Started May 2005; status: completed.
02
Drugs
Cisplatin micelle injection (HA132)
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT00262769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262769.